Mineralys Therapeutics, Inc Common Stock

Yahoo Finance • 7 days ago

Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?

Jon Congleton, Chief Executive Officer of Mineralys Therapeutics(NASDAQ:MLYS), reported the sale of 75,000 shares in multiple open-market transactions on March 31 valued at approximately $1.97 million, according to an SEC Form 4 filing. T... Full story

Yahoo Finance • 14 days ago

Immunic appoints biopharmaceutical executive Jon Congleton to board

Immunic appoints biopharmaceutical executive Jon Congleton to board Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to... Full story

Yahoo Finance • last month

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment... Full story

Yahoo Finance • 2 months ago

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidne... Full story

Yahoo Finance • 4 months ago

Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears

Key Points New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous period. As of September 30, Suvretta r... Full story

Yahoo Finance • 4 months ago

Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors – RADNOR,... Full story

Yahoo Finance • 5 months ago

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidne... Full story

Yahoo Finance • 5 months ago

Mineralys outlines NDA submission timeline and advances lorundrostat trials amid expanded clinical focus

Earnings Call Insights: Mineralys Therapeutics (MLYS) Q3 2025 MANAGEMENT VIEW * Jon Congleton, President and CEO, shared that Mineralys received pre-NDA feedback from the FDA with "no surprises" and is moving ahead with its NDA filing... Full story

Yahoo Finance • 5 months ago

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov... Full story

Yahoo Finance • 5 months ago

After-Hours Earnings Report for November 10, 2025 : OXY, RKLB, ASTS, RGTI, SARO, WULF, BLTE, PLUG, MLYS, TDW, BBAI, JAMF

The following companies are expected to report earnings after hours on 11/10/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Occidental Petroleum Corporation (OXY)is reporting for the quarter ending Sep... Full story

Yahoo Finance • 5 months ago

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Na... Full story

Yahoo Finance • 6 months ago

Mineralys Therapeutics Reaches Analyst Target Price

In recent trading, shares of Mineralys Therapeutics Inc (Symbol: MLYS) have crossed above the average analyst 12-month target price of $43.75, changing hands for $44.16/share. When a stock reaches the target an analyst has set, the analys... Full story

Yahoo Finance • 6 months ago

Stocks of possible M&A targets have been crushing the market. Goldman says these 6 are the most likely to get bought.

Mergers and acquisitions activity has surged in 2025, with a 29% increase in deal value. Goldman Sachs predicts another 15% rise in M&A deals in 2026, boosting candidate valuations. It flagged a list of firms it sees as M&A targets. Here a... Full story

Yahoo Finance • 7 months ago

Pfizer Inc. (PFE): A Bull Case Theory

We came across a bullish thesis on Pfizer Inc. on Investing With Purpose’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.'s share was trading at $24.15 as of September 18th. PFE’s trailing and forward P/... Full story

Yahoo Finance • 7 months ago

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

Key Points Shares of Nektar Therapeutics and Mineralys Therapeutics have risen sharply, and could run even further. Nektar is developing an experimental eczema treatment. Millions of patients with stubbornly high blood pressure could bene... Full story

Yahoo Finance • 7 months ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • 7 months ago

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need  

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, wo... Full story

Yahoo Finance • 7 months ago

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidn... Full story

Yahoo Finance • 7 months ago

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak

We recently published 10 Power Stocks Crushing Wall Street — 7 at All-Time Highs. Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the best performers on Tuesday. Mineralys surged to a new all-time high on Tuesday, as investors gobble... Full story

Yahoo Finance • 7 months ago

Mineralys Therapeutics prices upsized $250M stock offering

* Mineralys Therapeutics (NASDAQ:MLYS [https://seekingalpha.com/symbol/MLYS]) priced [https://seekingalpha.com/pr/20218530-mineralys-therapeutics-announces-pricing-of-upsized-250_0-million-underwritten-public] an upsized underwritten pub... Full story